Thermo Fisher Scientific Continues Support for COVID-19 Testing on Historically Black College and University Campuses

- Thermo Fisher Scientific Inc., (NYSE:TMO) the world leader in serving science, today announced continuing support for The Just Project a national initiative to provide COVID-19 testing to students, faculty and staff across more than 60 historically black colleges and universities (HBCUs) at no cost. A $7.5 million commitment for the 2021-2022 school year will once again provide diagnostic instruments, test kits and related supplies.

HBCU Testing

"A year after we launched The Just Project, COVID-19 cases are increasing again, and testing is critical to ensuring campus safety," said Fred Lowery , senior vice president and president for customer channels at Thermo Fisher Scientific. "Last year HBCUs nationwide administered more than 50,000 tests under the project, and infection rates at participating schools were below 1% with minimal academic disruption. We hope other schools will join the program as we extend it through the 2021-2022 school year."

The Just Project, named after pioneering biologist Ernest Everett Just , has created a nationwide testing infrastructure with the capacity to provide free testing for all 107 HBCUs in the U.S. Currently, eight on-campus labs serve as hubs to process samples for more than 60 participating HBCUs. Testing hubs include Florida A&M University , Hampton University , Howard University College of Medicine, Meharry Medical College , Morehouse School of Medicine , Texas Southern University , Tuskegee University and Xavier University of Louisiana .

"The Just Project has made a significant difference on our campus," said Rashid Mosavin, Ph.D., dean of the College of Pharmacy and Health Sciences, Texas Southern University . "With testing available on our campus as frequently as needed, we were able to welcome our students, faculty and staff back to campus for in-person learning with confidence."

James E.K. Hildreth , M.D., Ph.D., president and CEO of Meharry Medical College said, "We're grateful for Thermo Fisher's continued support of COVID-19 testing across HBCUs to serve a broad reach of their students. Testing is the core component of a robust model in preventing the spread of infectious disease. With these resources and testing components in place, we're able to make data-driven decisions and policies to support the health and safety of our students and community."

Given the focus on recruiting diverse talent, Thermo Fisher has also committed to hiring more than 500 HBCU alumni over three years, reinforcing a commitment to create a more inclusive workplace. Since August of 2020, more than 180 HBCU alumni have joined the company.

For more information on The Just Project, please visit our website .

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $35 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone:  781-622-1356
E-mail: rafael.tejada@thermofisher.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-continues-support-for-covid-19-testing-on-historically-black-college-and-university-campuses-301387537.html

SOURCE Thermo Fisher Scientific

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% ww), is now available to patients through BC PharmaCare, the public drug program of British Columbia

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Keep reading...Show less

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
{{ sections }}

Latest Press Releases

Related News

×